OpenAI Takes on Google With New AI Model Aimed at Drug Discovery
OpenAI and its competitors have increasingly focused on AI’s potential in the life sciences.
Photographer: Justin Sullivan/Getty Images
OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs.
The ChatGPT maker said Thursday that the model, GPT-Rosalind, is intended for life sciences research, such as helping glean insights from large volumes of data and turning scientific studies into health-care applications for patients. The model will be available initially as a research preview to some of the company’s business customers, OpenAI said. The initial users include drugmaker Amgen Inc., vaccine maker Moderna Inc. and the Allen Institute, a bioscience research nonprofit.